Literature DB >> 35777481

Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score.

Nicole J Kim1, Philip Vutien1, Kristin Berry2, George N Ioannou3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35777481      PMCID： PMC9586012          DOI： 10.1053/j.gastro.2022.06.057

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   33.883


× No keyword cloud information.
  7 in total

1.  Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Steven M Asch; Yumei Cao; Liang Li; Hashem B El-Serag
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.

Authors:  Hooman Farhang Zangneh; William W L Wong; Beate Sander; Chaim M Bell; Khalid Mumtaz; Matthew Kowgier; Adriaan J van der Meer; Sean P Cleary; Harry L A Janssen; Kelvin K W Chan; Jordan J Feld
Journal:  Clin Gastroenterol Hepatol       Date:  2018-12-20       Impact factor: 11.382

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

5.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

6.  HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.

Authors:  Amit G Singal; Emily Zhang; Manasa Narasimman; Nicole E Rich; Akbar K Waljee; Yujin Hoshida; Ju Dong Yang; Maria Reig; Giuseppe Cabibbo; Pierre Nahon; Neehar D Parikh; Jorge A Marrero
Journal:  J Hepatol       Date:  2022-02-06       Impact factor: 30.083

7.  The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System.

Authors:  Nicole J Kim; Karine Rozenberg-Ben-Dror; David A Jacob; Kristin Berry; George N Ioannou
Journal:  Am J Gastroenterol       Date:  2022-04-01       Impact factor: 12.045
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.